Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The company aims to halt or reverse liver scarring and resolve MASH to prevent complications such as cirrhosis and liver failure. Madrigal operates primarily in the pharmaceutical manufacturing sector and serves patients suffering from liver diseases, with its headquarters located in Conshohocken, Pennsylvania.
